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Abstract
Context—Measurement of dyspnea is important for clinical care and research.
Objectives—To characterize the relationship between the 0–10 Numerical Rating Scale (NRS) 
and four-level categorical Verbal Descriptor Scale (VDS) for dyspnea assessment.
Methods—This was a substudy of a double-blind randomized controlled trial comparing 
palliative oxygen to room air for relief of refractory breathlessness in patients with life-limiting 
illness. Dyspnea was assessed with both a 0–10 NRS and a four-level categorical VDS over the 
one-week trial. NRS and VDS responses were analyzed in cross section and longitudinally. 
Relationships between NRS and VDS responses were portrayed using descriptive statistics and 
visual representations.
Results—Two hundred twenty-six participants contributed responses. At baseline, mild and 
moderate levels of breathlessness were reported by 41.9% and 44.6% of participants, respectively. 
NRS scores demonstrated increasing mean and median levels for increasing VDS intensity, from a 
mean (SD) of 0.6 (±1.04) for VDS none category to 8.2 (1.4) for VDS severe category. The 
Spearman correlation coefficient was strong at 0.78 (P < 0.0001). Based on the distribution of 
NRS scores within VDS categories, we calculated test characteristics of two different cutpoint 
models. Both models yielded 75% correct translations from NRS to VDS; however, Model A was 
more sensitive for moderate or greater dyspnea, with fewer misses downcoded.
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Conclusion—There is strong correlation between VDS and NRS measures for dyspnea. 
Proposed practical cutpoints for the relationship between the dyspnea VDS and NRS are 0 for 
none, 1–4 for mild, 5–8 for moderate, and 9–10 for severe.
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Introduction
Dyspnea has been defined as “a subjective experience of breathing discomfort that consists 
of qualitatively distinct sensations varying in intensity. The experience derives from 
interactions among multiple physiological, psychological, social, and environmental 
factors.”1 A common experience among people with life-limiting illness, dyspnea 
prevalence has been reported to be as high as 65%, 70%, and 90% in advanced-stage 
patients with heart failure, lung cancer, and chronic obstructive pulmonary disease, 
respectively.2 Dyspnea is often intractable in advanced disease, frequently escalating in 
intensity as death approaches,3–6 eroding quality of life, psychological well-being, and 
social functioning.7
Dyspnea assessment has been an active area of research for many decades. The complex 
etiology of dyspnea, both pathophysiological and psychosocial, has proven challenging in 
developing tools that capture its multiple dimensions. Several recent reviews have examined 
existing validated measurement tools, highlighting the lack of consensus regarding how to 
best capture the complicated experience of dyspnea in both clinical and research settings.8,9 
The spectrum of measures includes single-item ordinal scales, functional assessment scales, 
global symptom inventories with dyspnea components, and multidimensional dyspnea 
scales.
The choice of scale depends on purpose, setting, and population. When precision and 
responsiveness to change are needed, complex multi-item scales may be preferable.10 
However, there are a range of scenarios where single-item dyspnea assessment scales are 
more appropriate, such as when part of routine clinical care, embedded in a larger group of 
patient-reported outcomes, or completed repeatedly at short intervals. Among single-item 
patient-reported scales, the Visual Analogue Scale,11 Numerical Rating Scale (NRS, e.g., 0 
= no breathlessness to 10 = worst breathlessness possible),12,13 and the modified Borg 
scale14,15 have all been validated, but none have been preferentially adopted.
The proliferation of assessment tools without standardized adoption of any single tool 
highlights the need for a simple breathlessness scale that can be reliably and practically used 
in the clinic, efficiently translating evidence between clinical care and clinical trials. Such a 
tool should be easily understood across diseases and settings, including advanced life-
limiting illness, and by patients and their families. To achieve this, it must focus on the 
subjective sensation of dyspnea and parallel other scales commonly used (e.g., pain 
assessment).
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Wilcock et al.13 advocated that the NRS is more practical than the Visual Analogue Scale for 
repeated measures in cancer patients. However, ordered categorical scales (e.g., none, mild, 
moderate, or severe) may be even more practical, would more clearly communicate what is 
meant clinically, and are less abstract for patients, especially if there is any cognitive 
impairment. For example, an ordered categorical scale is frequently used for pain 
assessment, and its relationship to the 0–10 NRS is well characterized (Fig. 1), although 
minor differences in cutpoints exist, depending on population and methods.16–18 The 
cutpoint between mild/moderate is often used as a lower threshold limit for eligibility in 
symptom controlled trials.19,20
The aim of this article, therefore, was to determine the relationship between an ordered 
categorical Verbal Descriptor Scale (VDS) of dyspnea and the dyspnea NRS, in a similar 
way that these two scales are related for pain assessment.
Methods
This was an a priori planned substudy intentionally embedded within an international, 
multicenter, double-blind, randomized controlled trial assessing the effect of palliative 
oxygen vs. room air in relief of refractory dyspnea.21 The parent study protocol was 
approved by the Duke University Health System Institutional Review Board, all nine local 
research and ethics committees or institutional review boards of all participating sites, and 
was registered with ClinicalTrials.gov (NCT00327873) and International Standard 
Randomised Controlled Trial Number (ISRCTN) (ISRCTN67448752).
Participants
In the parent study, patients (N = 239) were recruited from pulmonary, palliative care, 
oncology, and primary care services at five sites in Australia, two in the U.S., and two in the 
U.K. Participants were consenting adults with refractory dyspnea, partial pressure of oxygen 
in arterial blood (PaO2) >55 mmHg, and life-limiting illness where the underlying cause had 
been maximally treated. Participants had dyspnea at rest or with minimal exertion, 
corresponding to a Medical Research Council categorical dyspnea score of ≥3;22 however, 
patient data were pooled for this project, and there was no analysis according to the 
intervention used for the parent study. Additional eligibility criteria were that the 
participants must have been on stable medications for the seven days before randomization; 
hemoglobin >10 gm/dL; prognosis for survival of at least one month; and ability to complete 
the symptom diary, including ability to sufficiently understand English. Participants were 
randomized to medical air or oxygen, delivered at 2 L per minute via nasal cannula, for at 
least 15 hours daily for seven days.
Outcomes
The primary outcome was breathlessness right now, recorded by the participant twice a day 
(within 30 minutes of waking up [morning] and going to bed [evening]) in a diary with a 0–
10 NRS, anchored at 0 = not breathless at all and 10 = breathlessness as bad as you can 
imagine, which is a valid instrument for this population of patients.23 In addition to the 
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dyspnea NRS scale, participant diaries also included a four-point VDS for dyspnea severity 
(none, mild, moderate, or severe).
Thus, participants answered the following questions daily on both the NRS and VDS scales:
1. Morning assessment: How is your breathlessness right now?
2. Evening assessment: How is your breathlessness right now?
3. Evening assessment: How has your breathlessness been over the last 24 
hours, on average?
4. Evening assessment: What is the worst your breathlessness has been over 
the last 24 hours?
The participants were not instructed to respond to the questions in a specific order or to rate 
each scale independently; the daily diary provided to participants was ordered as shown 
previously. Participants were not asked to distinguish between the somatosensory intensity, 
affective distress, or other contributors to the perception of dyspnea in rating this item. 
Related symptoms, such as anxiety, functional limitations, and quality of life, were assessed 
with subsequent items in the diary.
For convenience, the preceding questions will henceforth be referred to as follows: Question 
1: “AM now,” Question 2: “PM now,” Question 3: “24 hours average,” and Question 4: “24 
hours worst.” The intervention comparing palliative oxygen and medical air lasted seven 
days, but patients began maintaining symptom diaries two days before the start of the 
intervention, thus documenting symptoms twice daily for nine days total.
Statistical Analysis
The relationship between the NRS and VDS responses for each of the four questions 
described previously was examined two ways: crosssectionally, using a single baseline time 
point (morning assessment on the day before the study intervention started, labeled Day −1) 
and longitudinally, across all time points. For the cross-sectional analysis, only participants 
who responded to both NRS and VDS forms of the question were included. For the 
longitudinal analysis, we created a single cross-tabulation of NRS and VDS scores 
regardless of question or time point (i.e., thus implicitly ignoring for the present purposes 
the multiple observations per patient). Descriptive statistics were used to evaluate and 
portray relationships. In both the cross-sectional and longitudinal analyses, missing data 
were not imputed. Although responses for both VDS and NRS were collected longitudinally 
throughout the study period, the purpose of this substudy was not to compare the 
responsiveness to change these rating scales.
Cutpoints were determined first by analyzing the distribution of NRS responses within each 
VDS category, looking for clear breaks in the data distribution. For example, if 80% of 
participants with a breathlessness NRS of 1 reported a VDS category of mild, NRS Level 1 
would be associated with the mild category for conversion purposes. In cases where no clear 
break could be identified, we made cutpoint determinations with the goal of minimizing 
instances where breathlessness is downgraded in translating the NRS to the VDS. An 
example of downgrading might be an instance where a patient’s recorded NRS score of 4 
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might be translated as mild in the VDS according to the derived cutpoints, but the patient 
had reported moderate dyspnea corresponding to this instance.
Results
Of the 239 participants, 61.5% were males and 63.5% had a diagnosis of chronic obstructive 
pulmonary disease (Table 1). Thirteen patients withdrew before the study started and 
completed no assessments and, therefore, were excluded from analysis. An additional 15 
participants withdrew before completing the final assessment. Across the entire study period, 
3.3% of morning NRS assessments and 3.6% of morning VDS assessments were missing—
predominantly because of dropout.
Cross-Sectional Analysis
The NRS and VDS were compared before any intervention (baseline, Day −1). Current 
breathlessness at the time of the morning assessment (AM now) was recorded for 222 
participants, with 41.9% reporting mild and 44.6% reporting moderate levels of 
breathlessness, and mean (SD) NRS of 4.5 (2.3) (Table 1). NRS values clustered within each 
VDS category. There was a direct relationship between mean (and median) NRS value with 
VDS category, with mean (SD) NRS scores of 0.3 (0.5) for VDS none category to 8.2 (1.1) 
for VDS severe category (Table 2). The NRS ranges that capture increasing percentages of 
patients in each VDS category were consistent (Table 2). The association between the NRS 
and VDS, reflected by Spearman’s correlation coefficient of 0.77 (P < 0.0001), was strong. 
Associations of similar strength, via Spearman’s correlation coefficient, were found for the 
other three questions on Day −1: Evening right now = 0.74; 24 hours average = 0.79; and 24 
hours worst = 0.76.
Longitudinal Analyses
Combining responses to all four questions across all nine days of the study yielded 3882 
paired observations for NRS and VDS. The results of analyses were substantively similar to 
those from the cross-sectional analysis of the AM now assessment on Day −1. The 
distribution of NRS scores within VDS categories is similar to that observed for the AM 
now assessment on Day −1 (Fig. 2). Specifically, the mean (SD) NRS scores were 0.61 (1.0) 
for VDS none, 3.4 (1.5) for VDS mild, 5.8 (1.4) for VDS moderate, and 8.2 (1.5) for VDS 
severe. The Spearman correlation coefficient for the VDS and NRS ratings was 0.78.
Cutpoint Analyses
Using the longitudinal data, analysis of the distribution of VDS category by NRS reveals 
that 94% of NRS responses of 0 correspond to VDS reports of none (Fig. 2). At NRS of 1, 
only 34% of responses corresponded with none; all but two of the remaining responses 
corresponded with mild. Similarly, the transition from moderate to severe was relatively 
clear, with 71% of patients with NRS of 8 reporting moderate breathlessness. At NRS of 9, 
70% reported severe breathlessness. The transition from mild to moderate is less clear, with 
49% of patients with NRS of 5 reporting mild dyspnea and 49% reporting moderate 
dyspnea.
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Based on the distribution of NRS scores within VDS categories, we examined the 
performance characteristics of two different cutpoint models. For Model A, NRS 0 
corresponded to VDS none, NRS 1–4 corresponded to VDS mild, NRS 5–8 corresponded to 
VDS moderate, and NRS 9–10 corresponded to VDS severe. In Model B, NRS 0 
corresponded to VDS none, NRS 1–5 corresponded to VDS mild, NRS 6–8 corresponded to 
VDS moderate, and NRS 9–10 corresponded to VDS severe (Table 2). Both models had a 
roughly 75% rate of correct translations from NRS to VDS; however, Model A had fewer 
misses downcoded (e.g., where the NRS attributed a lower VDS than the patient had 
reported at the corresponding time). Model A yields an 87% sensitivity and 78% specificity 
for moderate or severe dyspnea, whereas Model B yields only a 63% sensitivity but is more 
specific at 93% (Table 3).
Discussion
VDSs are practical tools for dyspnea monitoring in the clinic when more complicated scales 
such as a full 0–10 NRS may not be feasible. In this analysis, we demonstrate that the 
dyspnea VDS performs as expected, with tight clustering of NRS scores within VDS 
categories. Corresponding VDS and NRS scores have face validity.
In translating NRS to VDS, identification of NRS cutpoints for the transition from mild to 
moderate or moderate to severe is an important consideration. In pain, cutpoint identification 
has been addressed in multiple studies, across multiple disease states.24 In general, most 
studies yielded cutpoints identical to those identified by Serlin et al.,16 who used functional 
impairment to inform on pain severity in patients with metastatic cancer. The optimal NRS 
ranges identified in that study were 1–4 for mild, 5–6 for moderate, and 7–10 for severe. The 
consistency and similarities between the VDS for pain and ours for dyspnea suggest that 
verbal rating scales may have better inter-rater reliability. As shown previously in pain and 
confirmed here, there appears to be a uniform semantic meaning of the verbal descriptors 
mild, moderate, and severe.25,26 Notably, these verbal descriptors and their numerical 
associations differ from the modified Borg scale.
For dyspnea, we have identified reasonable clustering of NRS scores among VDS categories 
and established practical cutpoints. Based on the transition points (Fig. 2), in combination 
with the comparative performance characteristics, we propose the following cutpoints: 0 for 
none, 1–4 for mild, 5–8 for moderate, and 9–10 for severe (Table 3, Model A; Fig. 3). The 
cutpoints from none to mild and moderate to severe, based on the distribution of responses, 
are straightforward. The cutpoint from mild to moderate is less clear, though, because of the 
nearly even distribution of VDS and NRS around this transition. We made the 
recommendation for a mild to moderate cutpoint of 5 based on the superior sensitivity of this 
cutpoint to minimize downgrading. Clinically, downgrading symptom severity poses the risk 
of leaving clinical needs unaddressed, which is potentially more harmful than overestimating 
symptom burden. Of course, this consideration also must be balanced against the potential of 
exposing patients to unnecessary treatments if their symptoms are upgraded.
As discussed in the longitudinal analysis, the VDS tracked with the NRS, suggesting both 
are responsive to changes in dyspnea. Furthermore, this study demonstrates that, for these 
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data, numerical differences between pairs of subsequent verbal descriptors are equal (Table 
2), which may allow subsequent analyses to treat these VDS categories as interval variables, 
rather than ordinal, where this is appropriate. This provides practical opportunities for 
analyses when the VDS is incorporated into clinical research and quality monitoring 
programs.
The parallels we have drawn between pain and dyspnea are supported elsewhere in the 
literature,27 especially in light of growing evidence for dyspnea management strategies that 
parallel pain management strategies such as opioids.28 Similarly, there is more focus on 
integrated assessment and care models for dyspnea that parallel pain. For example, total 
breathlessness describes the concept whereby, like pain, breathlessness is experienced as an 
amalgamation of physical, psychosocial, and spiritual problems.25 This concept is supported 
by involvement of both cortical and subcortical central pathways in the perception of 
breathlessness,26,29 with strong similarities with those involved in the perception of pain and 
similar patterns demonstrated by functional magnetic resonance imaging.30
Pain management has become an integral component of most clinical assessments, but only 
after consensus regarding routine pain assessment tools was achieved. Similarly, as 
therapeutic options for dyspnea evolve, widespread clinical implementation will depend on 
ubiquitous and longitudinal dyspnea assessment using a simple, intuitive, and practical 
tool.31 The VDS and NRS are intended to fill this role, with the VDS being the most 
practical and efficient, and the NRS most useful when more fine-tuned information is 
needed. For purposes of simplicity, we anticipate that some health care providers, health 
systems, or electronic health records may choose to adopt the VDS for routine monitoring of 
dyspnea.
Beyond being simple, intuitive, and practical, the VDS scale and the proposed corresponding 
NRS cutpoints have implications for efficacy trials. In many pain management efficacy 
trials, the cutpoint for inclusion is the NRS cutpoint corresponding to moderate pain.19,20 
Considering the VDS to NRS cutpoints for moderate dyspnea identified in this study (i.e., 
moderate dyspnea corresponds to a starting point of NRS of 5), it is sensible to use an NRS 
of 5 or greater as a practical eligibility criterion for trials of novel dyspnea therapeutic 
interventions. Despite the distributional overlap between mild and moderate dyspnea, this 
cutpoint yields an 87% sensitivity and 78% specificity for moderate or severe dyspnea. If 
some enrolling centers use an NRS, whereas others use a VDS, understanding this 
relationship may be useful in screening records for recruitment or informing multicenter 
research.
This study has several limitations. As has previously been described, VDSs offer less 
granularity, are unidimensional, and may be insufficiently sensitive to detect small, but 
potentially meaningful, changes in symptom severity.32 Further work is needed to better 
characterize the reliability, validity, responsiveness, and determine clinically relevant 
changes of this VDS for breathlessness, all of which are beyond the scope of this analysis. 
Additionally, the assumption that increments between each ordinal category are numerically 
similar is frequently cited as a limitation of VDSs. In this study, however, the difference in 
mean NRS score for each VDS category was very consistent (Table 2), suggesting that, at 
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least from a population standpoint, there is a consistent incremental stepwise relationship 
between the VDS categories. One limitation of single-item scales is that they can be 
influenced by the affective experience of dyspnea and may not completely isolate the 
somatosensory intensity of dyspnea. These instruments are not designed to discriminate 
between the various contributors to dyspnea (e.g., pulmonary disease, mood disturbance, 
lack of social support, existential distress). It has been demonstrated that single-item ratings 
of pain are more reflective of psychosocial distress than pathophysiologic processes.33 
Neither the parent study nor this substudy intended to evaluate the primary drivers of the 
experience of breathlessness. Thus, heterogeneity in the components of breathlessness 
between participants is likely; in fact, there was marked heterogeneity among the diagnoses 
driving the breathlessness in this study. These scales are not intended to replace such 
instruments in research protocols where the components of breathlessness are of interest.
As dyspnea management continues to evolve, implementation of an assessment tool that is 
clinically practical and intuitive is necessary. We have demonstrated good correlation 
between verbal descriptor and NRSs for dyspnea in a population with life-limiting illness 
and refractory dyspnea and have identified practical cutpoints relating the NRS to VDS. 
These scales are practical and clinically intuitive and can be easily integrated into routine 
clinical practice and provide cutpoints that can be used to screen for inclusion in clinical 
dyspnea management trials.
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Fig. 1. 
Practical relationship between Numerical Rating Scale and Verbal Descriptor Scale for pain 
(based on results from Refs.15,16).
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Fig. 2. 
Distribution of Verbal Descriptor Scale (VDS) categories at each Numerical Rating Scale 
(NRS) score, reflecting current breathlessness across all study days.
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Fig. 3. 
Practical relationships between Numerical Rating Scale and Verbal Descriptor Scale for pain 
(top, based on results from Refs.15,16) and breathlessness (bottom, based on this study).
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Table 1
Baseline Demographics and Breathlessness Ratings Before Intervention (Day −1)
N = 239 Mean (SD) or %
Age, yrs 73 (10)
Male 62%
Chronic obstructive pulmonary disease 64%
Cancer 16%
Baseline PaO2, mm Hg 76 (12)
Baseline dyspnea intensity
  NRS (N = 225) 4.5 (2.3)
  None (VDS) 6.8%
  Mild (VDS) 41.9%
  Moderate (VDS) 44.6%
  Severe (VDS) 6.7%
NRS = Numerical Rating Scale; VDS = Verbal Descriptor Scale.
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Table 2
Cross-Sectional Analyses Compared with Longitudinal Analyses of VDS and NRS Dyspnea Scores, 
Reflecting Current Morning Breathlessness at Baseline (Day −1) as Compared with All Entries on All Days
Cross-Sectional
Analysis
Longitudinal
Analysis
Corresponding NRS
VDS Categories N Mean (SD) N Mean (SD)
None 15 0.33 (0.49) 455 0.62 (1.0)
Mild 93 3.4 (1.5) 1898 3.4 (1.5)
Moderate 99 5.8 (1.4) 1386 5.9 (1.4)
Severe 15 8.2 (1.1) 143 8.2 (1.5)
Total 222 3882
VDS = Verbal Descriptor Scale; NRS = Numerical Rating Scale.
J Pain Symptom Manage. Author manuscript; available in PMC 2016 September 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Wysham et al. Page 16
Ta
bl
e 
3
M
et
ric
s A
ss
oc
ia
te
d 
w
ith
 T
w
o
 M
od
el
s f
or
 C
ut
po
in
ts 
Be
tw
ee
n 
M
ild
 a
nd
 M
od
er
at
e 
Br
ea
th
le
ss
ne
ss
Se
ns
iti
v
ity
 (%
)
Sp
ec
ifi
ci
ty
 (%
)
%
 C
or
re
ct
a
%
 U
pc
od
ed
b
%
 D
ow
n
co
de
dc
M
od
el
 A
 (0
, 1
–4
, 5
–8
, a
nd
 9–
10
)
87
78
74
.8
17
.8
9.
6
M
od
el
 B
 (0
, 1
–5
, 6
–8
, a
nd
 9–
10
)
63
93
74
.7
8.
1
17
M
od
el
 A
 u
se
s a
 N
um
er
ic
al
 R
at
in
g 
Sc
al
e 
(N
RS
) c
utp
oin
t o
f 4
, w
he
rea
s M
od
el 
B 
us
es 
an
 N
RS
 cu
tpo
int
 of
 5.
 Se
ns
itiv
ity
 a
nd
 sp
ec
ifi
ci
ty
 o
f t
he
se
 c
ut
po
in
ts 
to
 d
ist
in
gu
ish
 m
od
er
at
e 
or
 g
re
at
er
 d
ys
pn
ea
 a
re
 
re
po
rte
d.
 T
he
 %
 c
or
re
ct
, u
pc
od
ed
, a
nd
 d
ow
n
co
de
d 
re
fle
ct
s t
he
 a
gg
re
ga
te
 o
f a
ll 
pa
tie
nt
s, 
al
l q
ue
sti
on
s, 
an
d 
al
l d
ay
s.
a P
er
ce
nt
 o
f p
at
ie
nt
s w
he
re
 th
e 
N
RS
 a
nd
 V
er
ba
l D
es
cr
ip
to
r S
ca
le
 (V
DS
) w
ere
 eq
uiv
al
en
t.
b P
er
ce
nt
 o
f p
at
ie
nt
s w
he
re
 th
e 
N
RS
 a
ttr
ib
u
te
d 
a 
hi
gh
er
 V
D
S 
th
an
 th
e 
pa
tie
nt
s a
ttr
ib
u
te
d 
th
em
se
lv
es
.
c P
er
ce
nt
 o
f p
at
ie
nt
s w
he
re
 th
e 
N
RS
 a
ttr
ib
u
te
d 
a 
lo
w
er
 V
D
S 
th
an
 th
e 
pa
tie
nt
s a
ttr
ib
u
te
d 
th
em
se
lv
es
.
J Pain Symptom Manage. Author manuscript; available in PMC 2016 September 01.
